Overview
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Indication
用于防治高血压、冠心病、心绞痛和充血性心力衰竭。
Associated Conditions
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/03/20 | Early Phase 1 | Completed | |||
2014/06/20 | Phase 3 | Completed | |||
2014/05/13 | Not Applicable | UNKNOWN | |||
2013/07/10 | Phase 1 | Completed | |||
2013/02/06 | Phase 2 | Terminated | |||
2012/08/06 | Not Applicable | Completed | |||
2009/05/28 | Phase 2 | Completed | |||
2008/09/16 | Phase 2 | Completed | |||
2008/01/15 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Epic Pharma, LLC | 42806-264 | ORAL | 5 mg in 1 1 | 3/15/2021 | |
| Carilion Materials Management | 68151-1333 | ORAL | 5 mg in 1 1 | 3/12/2012 | |
| Actavis Pharma, Inc. | 16252-539 | ORAL | 2.5 mg in 1 1 | 11/30/2023 | |
| Elite Laboratories, Inc. | 64850-910 | ORAL | 2.5 mg in 1 1 | 12/28/2022 | |
| Actavis Pharma, Inc. | 16252-540 | ORAL | 5 mg in 1 1 | 11/30/2023 | |
| Epic Pharma, LLC | 42806-263 | ORAL | 2.5 mg in 1 1 | 3/15/2021 | |
| AvKARE | 42291-062 | ORAL | 2.5 mg in 1 1 | 6/9/2023 | |
| Elite Laboratories, Inc. | 64850-911 | ORAL | 5 mg in 1 1 | 12/28/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.